



Arrowhead Pharmaceuticals, Inc.
Investor Relations Department
225 South Lake Avenue
Suite 1050
Pasadena, CA 91101
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ARWR

Last Trade:	1.88
Trade Time:	4:00 PM ET Jul 26, 2017
Change:	0.28 (+17.500%)
Day Range	1.63 - 1.89
52-Week Range	1.20 - 8.22
Volume	2,380,783


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 9, 2017*
[Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635\(c\)\(4\)](#)
- May 3, 2017*
[Arrowhead Reports Fiscal 2017 Second Quarter Results](#)
- Apr 26, 2017*
[Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results](#)
- Apr 24, 2017*
[Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data at The International Liver Congress™](#)
- Apr 20, 2017*
[Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Dec 14, 2016*
[Annual Report \(10-K\)](#)
- Feb 1, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 3, 2017*
[Quarterly Report \(10-Q\)](#)
- Feb 6, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2016*
[Quarterly Report \(10-Q\)](#)